Assessment of the MACPT tool to facilitate communication
Research type
Research Study
Full title
Assessment of the ‘Managing Advanced Cancer Pain Together’ (MACPT) tool to facilitate communication on total cancer pain between advanced cancer patients and their healthcare professionals
IRAS ID
250392
Contact name
Barry Quinn
Contact email
Sponsor organisation
Amgen Ltd.
Duration of Study in the UK
0 years, 6 months, 19 days
Research summary
Assessment of the 'Managing Advanced Cancer Pain Together' (MACPT) tool to facilitate communication on total cancer pain between advanced cancer patients and their healthcare professionals (HCPs) during routine Standard-of-Care (SoC) consultations.
The experience of pain in cancer is widely accepted as a major threat to quality of life, and the relief of pain has emerged as a priority in oncology care. It is believed that the treatment of pain in advanced cancer may be more successful if patients felt that they were able to discuss the issue more openly with their HCPs, as well as speak more freely about other aspects of pain rather than focusing on their physical state. To help address this, a paper-based conversation tool has been developed.
The primary objective of this study is to assess the impact of the MACPT tool on patient- and HCP- reported overall satisfaction of their conversation during routine SoC consultations.
The secondary objectives are to assess the impact of the MACPT tool on patient- and HCP- reported satisfaction on specific aspects of their conversation during face-to-face routine SoC consultations, to describe the frequency of the tool words selected by the patients, and to describe both patient- and HCP-reported usefulness of the MACPT conversation tool to identify key aspects of the patient’s total pain experience. Other objectives will explore perceptions of pain from the HCP and patient perspective.
People with advanced breast cancer, prostate cancer, lung cancer or multiple myeloma with an upcoming routine SoC consultation will be eligible and will be recruited from clinical sites in the UK, France and Germany. Amgen Inc are funding the study.
Eligible patients and their HCPs (study participants) will be exposed to the MACPT tool at one of their routine SoC consultations. Participants will be asked to complete questionnaires before and after exposure to the tool.
REC name
HSC REC A
REC reference
18/NI/0147
Date of REC Opinion
11 Sep 2018
REC opinion
Further Information Favourable Opinion